BioTech IP Review

US20250161302A1 (continuation of extended release upadacitinib formulations)
Filing Date: January 17, 2025
Priority Date: December 29, 2020

What This Patent Covers

This patent family protects extended-release formulations of upadacitinib, the active small molecule in Rinvoq, AbbVie’s hugely successful oral Janus kinase (JAK) inhibitor for autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and more. It describes:

• Formulated compositions that control the release profile of upadacitinib in tablet form, improving dosing consistency and therapeutic effect.¹
• Pharmaceutical methods and uses of these formulations in treating inflammatory and immune-mediated diseases with optimized pharmacokinetics.¹

These formulation claims enhance AbbVie’s ability to protect extended-release upadacitinib formulations, which help sustain Rinvoq’s clinical performance and commercial value.

---

Why This Is Important

Rinvoq has been a key revenue driver for AbbVie — generating billions each year. In **September 2025, AbbVie announced settlement agreements with all generic challengers that extend U.S. patent protection until at least April 2037 (assuming pediatric exclusivity) — roughly five years longer than previously expected. This moves generics off the market and significantly enhances future revenue forecasts.

Analysts have called this extension a major win for the company, helping to sustain and potentially grow shares as Rinvoq continues to drive immunology sales into the next decade.

Rinvoq’s continued exclusivity under these patents supports AbbVie’s broader business strategy as it balances the post-Humira landscape. Even after Humira lost exclusivity in 2023, Rinvoq — along with other products — helped stabilize revenues, with analysts projecting tens of billions in combined sales over coming years.

Beyond rheumatoid arthritis, Rinvoq is being explored for additional indications like vitiligo, lupus, and hidradenitis suppurativa, potentially further expanding the drug’s market and strengthening the value of its patent estate.

---

Summary

AbbVie’s continued patent applications for upadacitinib (e.g., US20250161302A1) and related formulation patents are among the company’s most financially significant intellectual property assets. They underpin the extended exclusivity of Rinvoq, allowing AbbVie to sustain dominant market position and protect multi-billion dollar annual sales well into the 2030s. Through strategic litigation settlements extending protection to 2037, this patent portfolio remains central to AbbVie’s long-term commercial success.